<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125436</url>
  </required_header>
  <id_info>
    <org_study_id>1KL2RR024990</org_study_id>
    <nct_id>NCT01125436</nct_id>
  </id_info>
  <brief_title>A Trial of Vitamin D Therapy in Patients With Heart Failure</brief_title>
  <official_title>A Randomized Placebo Controlled Trial of Vitamin D Therapy in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if vitamin D will improve physical performance in
      older adults with heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak VO2</measure>
    <time_frame>baseline</time_frame>
    <description>Cardiopulmonary stress testing with the Peak VO2 representing maximal aerobic capacity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak VO2</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiopulmonary stress testing with the Peak VO2 representing maximal aerobic capacity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>muscle strength</measure>
    <time_frame>baseline</time_frame>
    <description>strength of the proximal lower extremity muscles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle strength</measure>
    <time_frame>6 months</time_frame>
    <description>strength of the proximal lower extremity muscles</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Heart Failure</condition>
  <condition>Aerobic Capacity</condition>
  <condition>Strength</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutritional supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>50,000 IU weekly for 6 months</description>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Placebo weekly for 6 months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NYHA class II-IV

          -  Able to walk

          -  Serum 25OHD level 37.5 ng/ml or less

          -  Fully titrated on heart failure medications

        Exclusion Criteria:

          -  Osteoporosis

          -  Primary hyperparathyroidism or hypercalcemia.

          -  Nephrolithiasis

          -  Hemo or peritoneal dialysis and/or creatinine of &gt; 2.5

          -  Current use of daily vitamin D greater than 400 IU, corticosteroids,PTH, androgen or
             estrogen

          -  Current illicit drug user or &gt; 3 alcoholic drinks a day

          -  Metastatic or advanced cancer

          -  Myocardial infarction in the preceding 6 months

          -  Medications which can lower vitamin D levels or bioavailability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospitals/Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2010</study_first_posted>
  <last_update_submitted>July 1, 2011</last_update_submitted>
  <last_update_submitted_qc>July 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Rebecca S. Boxer, MD</name_title>
    <organization>Case Western Reserve University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

